Phase I, Multicenter, Open-label, Dose-escalating, Clinical and Pharmacokinetic Study of PM060184 Administered Intravenously to Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 29 Sep 2015
At a glance
- Drugs PM 060184 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors PharmaMar
- 18 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Sep 2015 According to a PharmaMar media release, data from this study will be presented at the 18th ECCO - 40th ESMO European Cancer Congress (ECC 2015).
- 23 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.